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Abstract
Background: The emergence of multidrug-resistant (MDR) and extended-spectrum beta-lactamase (ESBL)-
producing uropathogens has complicated the treatment of urinary tract infections (UTI). Paediatric UTI is a common
illness, which if not treated properly, may lead to acute and long-term complications, such as renal abscess,
septicaemia, and renal scarring. This study aimed to determine the prevalence of MDR and ESBL-producing
uropathogens among children.
Methods: During the study period (April 2017–April 2018), midstream urine samples were collected following
aseptic procedures from children < 16 years in Siddhi Memorial Hospital. Standard culture and biochemical tests
were performed to identify uropathogens and antimicrobial susceptibility test was done by modified Kirby-Bauer
disc diffusion method following Clinical and Laboratory Standard Institute (CLSI) guidelines. ESBL-producing
uropathogens were screened by ceftazidime (30 μg) and cefotaxime (30 μg) discs, and confirmed by the
combination disc tests: ceftazidime + clavulanic acid (30/10 μg) or cefotaxime + clavulanic acid (30/10 μg) as
recommended by CLSI.
Results: We processed 5545 non-repeated urine samples from the children with symptoms of UTI. A significant
growth of uropathogens was observed in 203 samples (3.7%). The median age of the children was 24 months
(interquartile range (IQR), 12–53 months). Escherichia coli (n = 158, 77.8%) and Klebsiella pneumoniae (n = 30, 14.8%)
were common among the uropathogens. Among them, 80.3% were resistant to amoxycillin and 51.2% were
resistant to cotrimoxazole. Most of them were susceptible to amikacin, nitrofurantoin, and ofloxacin. MDR was
detected in 34.5% (n = 70/203) and ESBL producers in 24.6% (n = 50/203) of them. The proportion of MDR isolates
was higher in children < 5 years (n = 59/153, 38.6%) than children ≥ 5 years (n = 11/50, 22%) (P = 0.03).
Conclusions: Nitrofurantoin, ofloxacin, and amikacin can be used for the empirical treatment for UTI in children in
Bhaktapur, Nepal. MDR and ESBL-producing uropathogens are prevalent; this warrants a continuous surveillance of
antimicrobial resistance.
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Introduction
Urinary tract infection (UTI) is a common cause of ill-
ness in children. Gastrointestinal bacteria, such as
Escherichia coli and Klebsiella pneumoniae, cause UTIs.
Effective antimicrobial treatment of these infections is
necessary; if untreated, they may complicate to renal ab-
scess, septicaemia, renal scarring, and renal failures
which can be life threatening in children [1, 2]. Not all
UTI cases can be diagnosed with an isolation of a uro-
pathogen and its antimicrobial susceptibility can be
known; therefore, understanding the distribution of uro-
pathogens and their resistance patterns will help the
doctors and caregivers choose appropriate antibiotics for
an empirical treatment [3].
The growing prevalence of antimicrobial resistance
among uropathogens is an enormous concern. The in-
crease in proportion of multidrug-resistance (MDR) and
ESBL-producing uropathogens in children has not only
limited the treatment by rendering the first-line antibi-
otics ineffective but also complicated the treatment by
increasing the hospital stay. The problem of antimicro-
bial resistance has become worse in resource-limited
countries where antimicrobials are available over-the-
counter [4–6]. Surveillance of resistance patterns in
these countries is thus vital to help doctors and care-
givers prescribe effective treatment to patients. Such sur-
veillance also informs policy makers to develop public
health measures that may help decrease the prevalence
of resistant organisms, which may decrease economic
burden in the community [7–9].
In this study, we aimed to determine the prevalent
uropathogens, their antimicrobial susceptibility, and the
prevalence of MDR and ESBL producers in children at-
tending a paediatric hospital in Nepal with symptoms of
UTI.
Methods
Study design and setting
We carried out this cross-sectional study from April 14,
2017 to April 13, 2018, in the Department of Microbiol-
ogy, Siddhi Memorial Hospital (SMH) in Bhaktapur,
Nepal. SMH is a 50-bedded hospital that provides ter-
tiary care to children. We included children less than 16
years of age in this study.
Laboratory methods
We collected urine specimens following aseptic proce-
dures, such as midstream urine, catheterisation, and
suprapubic aspiration from children with clinical symp-
toms suggestive of a possible UTI. We transported the
urine samples to the laboratory immediately and proc-
essed by the semi-quantitative streaking method. We in-
oculated 10 μL of urine onto a cysteine lactose
electrolyte deficient (CLED) agar plate using a sterile
calibrated wired loop. Inoculated plates were incubated
at 37 °C in aerobic conditions for 18 h. We diagnosed a
UTI when we observed a significant growth (≥ 105col-
ony-forming units/mL) of a single organism. To isolate
and identify the organisms, we performed standard
microbiological methods including colony morphology,
Gram staining, catalase, oxidase, and in-house set of bio-
chemical tests [10].
Antimicrobial susceptibility testing
We used the modified Kirby-Bauer method to determine
the susceptibility of bacterial isolates on Mueller Hinton
agar (Oxoid, UK) following the guidelines of the Clinical
and Laboratory Standards Institute (CLSI), Wayne, USA
[11]. We tested common antimicrobials that we pre-
scribe in our hospital by using these antimicrobial discs:
amoxycillin (10 μg), amikacin (30 μg), cefazolin (30 μg),
cefotaxime (30 μg), ceftazidime (30 μg), cotrimoxazole
(1.25/23.7), ofloxacin (5 μg), and nitrofurantoin (300 μg).
We assigned the results of susceptibility tests susceptible
or resistant according to the zone size standards of CLSI.
We defined MDR isolate if it showed resistance to at
least one antimicrobial from the three groups of the
first-line antimicrobials: beta-lactam, aminoglycoside,
quinolone, sulphonamide, and nitrofuran.
Screening and confirmation of ESBL-producing isolates
We screened all Gram-negative bacilli for ESBL produc-
tion. We tested the susceptibilities to third-generation
cephalosporins by using ceftazidime (30 μg) and cefotax-
ime (30 μg) discs. As recommended by CLSI, we consid-
ered the isolates as potential ESBL producers if the zone
of inhibition was ≤ 22mm for ceftazidime or ≤ 27mm for
cefotaxime. The potential ESBL producers were then ex-
amined for confirmation by the combination disc test as
the CLSI guideline. In this test, we tested the isolates
against a ceftazidime (30 μg) disc and a ceftazidime + cla-
vulanic acid (30/10 μg) combination disc, and we com-
pared the inhibition zones around these discs. We
considered that the test was positive for the confirmation
of ESBL producers if the inhibition zone diameter was ≥ 5
mm larger with the combination disc than the ceftazidime
disc. Similarly, we also performed the confirmation test
with a cefotaxime (30 μg) disc and a cefotaxime + clavula-
nic acid (30/10 μg) combination disc in all potential iso-
lates; the results were interpreted as positive if the
inhibition zone diameter was ≥ 5mm larger with the com-
bination disc than the cefotaxime disc. Having positive re-
sults in any one of these two confirmatory tests, we
confirmed the isolates as ESBL producers.
Data analysis
We analysed the data in Stata 14 (Stata Corp, Texas).
The chi-squared test was used to compare the
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proportions of isolates between males and females, and
between younger than 5 years and equal or older than 5
years.
Results
The total number of urine samples processed during the
study period was 5545. The number of isolates with the
significant growth was 203. The prevalence of UTIs was
3.7% among these children. The median age of the chil-
dren was 24 months (IQR, 12–53 months) and there
were 101 male and 102 female children. Three-quarters
(n = 153, 75.3%) of isolates were from the children less
than 5 years. E. coli was the most common isolated uro-
pathogen (n = 158, 77.8%) followed by K. pneumoniae (n
= 30, 14.8%) (Fig. 1). The proportion of E. coli in female
children was 83.3% and 72.2% (P = 0.05) in male chil-
dren. There were no significant differences in the pro-
portions of bacterial isolates between males and females,
and between children less than 5 years and the older-
aged groups (Table 1).
We show the antimicrobial resistance patterns of the
uropathogens in Table 2. E. coli was most susceptible to
nitrofurantoin and amikacin, whereas K. pneumoniae
was most susceptible to amikacin and ofloxacin. A high
proportion of the uropathogens was resistant to amoxy-
cillin, cefazolin, cefotaxime, and cotrimoxazole, whereas
amikacin, nitrofurantoin, and ofloxacin were the antimi-
crobials to which most uropathogens were susceptible
(Fig. 2).
We detected multidrug-resistance in 34.5% (n = 70/
203) of the uropathogens. The proportions of MDR in
male and female children were similar (n = 34/101,
33.7% in male vs n = 36/102, 35.3% in female children)
(P = 0.8). We observed a higher proportion of MDR in
children younger than 5 years (n = 59/153, 38.6%) than
older aged group (n = 11/50, 22%) (P = 0.03) (Fig. 3).
We detected ESBL producers in 24.6% (n = 50/203) of
the uropathogens. The proportions of ESBL producers
were not different between male (n = 28/101, 27.7%) and
female children (n = 22/102, 21.6%) (P = 0.3), and be-
tween children under 5 years (n = 38/153, 24.8%) and
older-aged children (n = 12/50, 24%) (P = 0.9). MDR
was detected in 34.2% of E. coli and 36.7% of K. pneumo-
niae isolates. ESBL producers were detected in 27.2% of
E. coli and 23.3% of K pneumoniae isolates (Table 3).
Discussion
This study shows that E. coli and K. pneumoniae were
common uropathogens in the children who attended to
Siddhi Memorial Hospital, Bhaktapur, Nepal. Most of
the uropathogens were resistant to the commonly pre-
scribed antimicrobials, such as amoxycillin and cotri-
moxazole, that render these antimicrobials ineffective for
the empirical treatment. Multidrug-resistance and ESBL
producers were detected in high proportions, and MDR
was more common in children younger than 5 years
than older children.
Urinary tract infections are caused by Gram-positive
and Gram-negative bacteria, and fungi [9]. E. coli and K.
pneumoniae are the common causes of UTI in children
and adults [9, 12]. In this study, all the isolated uro-
pathogens were Gram-negative bacteria, 77.8% were E.
coli and 14.8% were K. pneumoniae, together they com-
prised 92.6% of all the uropathogens. These findings
were comparable with the studies from Turkey, Ethiopia,
Iran, and Nepal [12–15].
Uropathogens generally reside in the gut. When the
periurethral region is contaminated with these bacteria,
a UTI starts by the development of colonisation of ur-
ethra and migration of the bacteria to the bladder [9]. In
lack or failure of treatment, a UTI can result in serious
sequelae that include renal abscess, renal scarring, and
chronic renal failure [1, 2].
Fig. 1 Distribution of uropathogens in children in Siddhi Memorial Hospital, Bhaktapur, Nepal. The bar graph shows the proportion of the seven
types of uropathogens isolated (n = 203) from 5545 non-repeated urine samples. E. coli (77.8%) and K. pneumoniae (14.8%) were the predominant
uropathogens isolated
Raya et al. Tropical Medicine and Health           (2020) 48:65 Page 3 of 7
The prevalence of antimicrobial resistance to first-line
antimicrobials for UTIs in children has increased in
resource-limited countries. A systematic review on 58
observation studies shows the pooled prevalence of re-
sistance in E. coli is higher—79.8% to ampicillin, 60.3%
to co-amoxiclav, and 26.8% to ciprofloxacin—in non-
OECD (Organisation for Economic Co-operation and
Development) countries than the resistance of E. coli—
53.4% to ampicillin, 8.2% to co-amoxiclav, and 2.1% to
ciprofloxacin—in OECD countries [4]. In this study, we
found that 80.3% of isolates were resistant to amoxycil-
lin, 62.1% resistant to cefotaxime, and 51.2% resistant to
cotrimoxazole. These are the first-line treatment of UTIs
in children in Nepal. One of the reasons for the high
prevalence of resistance to routine antibiotics is the
availability of over-the-counter antimicrobials [4]. Be-
cause of the high prevalence of resistant uropathogens,
the first-line antimicrobials, such as amoxycillin and
cotrimoxazole, may be ineffective and only a few antimi-
crobials are left for effective treatment of UTIs. Our
study showed that most uropathogens, which are
community-acquired, in Bhaktapur, Nepal, were suscep-
tible to nitrofurantoin, ofloxacin, and amikacin. Amoxy-
cillin and cotrimoxazole, which are inexpensive, easily
available, and have fewer side effects, can no longer be
prescribed as an empirical treatment in this region due
to the high level of antimicrobial resistance acquired by
the uropathogens.
Increasing resistance of uropathogens to three or more
groups of antimicrobials (MDR) has become a severe
threat to the health care system [16]. Gram-negative
bacteria that cause UTIs have developed resistance to
many drug classes, including beta-lactams, aminoglyco-
side, and quinolones. In this study, we found 34.2% of E.
coli and 36.7% of K. pneumoniae were MDR. Our find-
ings were similar to those of Shrestha et al. who re-
ported that 34% isolates were MDR in Dharan, a city in
the eastern part of Nepal, in 2018 [17]. However, few
studies in Kathmandu showed a higher proportion
(52.3%, 64.9%) of MDR than our study in E. coli [12, 18].
The higher prevalence of MDR in Kathmandu than
Bhaktapur may be due to bigger general hospitals in
Kathmandu, where children and adults with more risk
factors for MDR are treated, than in Bhaktapur. Previous
antimicrobial use, previous hospitalisation, urinary cath-
eterisation, and urinary tract anomalies are some of the
known risk factors for MDR [19, 20]. We found that
MDR was significantly more prevalent in children youn-
ger than 5 years than older children. One plausible ex-
planation for this observation can be that the children
younger than 5 years receive antimicrobials more often
for repeated infections, such as acute respiratory
Table 1 Distributions of uropathogens by age and sex of children in Siddhi Memorial Hospital, Bhaktapur, Nepal
Uropathogens Sex Age
Male, no. (%) (n = 101) Female, no. (%) (n = 102) < 5 years, no. (%) (n = 153) ≥ 5 years, no. (%) (n = 50)
E. coli 73 (72.2) 85 (83.3) 118 (77.1) 40 (80.0)
K. pneumoniae 19 (18.8) 11 (10.8) 24 (15.7) 6 (12.0)
K. oxytoca 4 (4.0) 3 (2.9) 5 (3.2) 2 (4.0)
P. mirabilis 4 (4.0) 0 (0.0) 4 (2.6) 0 (0.0)
P. vulgaris 1 (1.0) 1 (1.0) 1 (0.7) 1 (2.0)
C. freundii 0 (0.0) 1 (1.0) 0 (0.0) 1 (2.0)
Acinetobacter spp. 0 (0.0) 1 (1.0) 1 (0.7) 0 (0.0)
Table 2 Antimicrobial resistance patterns of uropathogens in children in Siddhi Memorial Hospital, Bhaktapur, Nepal
Antimicrobials Uropathogens
E. coli, no. (%)
(n = 158)
K. pneumoniae, no.
(%) (n = 30)
K. oxytoca, no.
(%) (n = 7)
P. mirabilis,no.
(%) (n = 4)
P. vulgaris, no.
(%) (n = 2)
C. freundii, no.
(%) (n = 1)
Acinetobacter spp.,
no. (%) (n = 1)
Amikacin 22 (13.9) 2 (6.7) 1 (14.3) 1 (25) 0 (0) 0 (0) 0 (0)
Amoxycillin 126 (79.7) 28 (93.3) 5 (71.4) 2 (50) 1 (50) 1 (100) 0 (0)
Cefazolin 111 (70.3) 20 (66.7) 5 (71.4) 2 (50) 1 (50) 1 (100) 1 (100)
Cefotaxime 103 (65.2) 19 (63.3) 2 (28.6) 0 (0) 1 (50) 0 (0) 1 (100)
Ceftazidime 75 (47.5) 15 (50) 1 (14.3) 0 (0) 0 (0) 0 (0) 0 (0)
Cotrimoxazole 82 (51.9) 18 (60) 2 (28.6) 1 (25) 1 (50) 0 (0) 0 (0)
Ofloxacin 66 (41.8) 7 (23.3) 0 (0) 1 (25) 0 (0) 0 (0) 0 (0)
Nitrofurantoin 9 (5.7) 13 (43.3) 2 (28.6) 4 (100) 2 (100) 0 (0) 1 (100)
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infections and gastrointestinal infections, than the older
children, which help the bacteria to develop resistance
to multiple antimicrobials.
Infections with ESBL-producing organisms in chil-
dren are associated with longer hospital stays, fre-
quent complications, and increased mortality [21].
ESBL-producing Enterobacteriaceae causes one in
seven (14%) UTI in children [6]. In our study, 24.6%
of uropathogens were ESBL producers. Some other
studies in Nepal also show a high prevalence of ESBL
producers, 40% in Dharan and 38.9% in Kathmandu
[17, 18]. This discrepancy of prevalence of ESBL pro-
ducers may be due to the studies that were carried
out in general hospitals where complicated UTI cases,
including adult patients, were treated and are located
in different geographical regions [6, 21]. Overall, these
studies show a high prevalence of ESBL producers
among uropathogens in Nepal.
Fig. 2 Antimicrobial resistance patterns of uropathogens in children in Siddhi Memorial Hospital, Bhaktapur, Nepal. The bar graph shows the
proportion of uropathogens that showed antimicrobial resistance to commonly used eight antimicrobials in the hospital. The uropathogens were
most susceptible to amikacin and nitrofurantoin and resistant to cefotaxime, cefazolin, and amoxycillin
Fig. 3 Distributions of MDR and ESBL-producing uropathogens in
children. The bar graph shows the comparison of the proportions of
MDR and ESBL-producing uropathogens between children < 5 years
old and ≥ 5 years old. The proportions of MDR were 38.6% (n = 59/
153) in < 5 years and 22% (n = 11/50) in ≥ 5 years old children (P
= 0.03)
Table 3 Prevalence of MDR and ESBL-producing uropathogens
in children in Siddhi Memorial Hospital, Bhaktapur, Nepal
Uropathogens MDR (%) ESBL (%)
E. coli (n = 158) 54 (34.2) 43 (27.2)
K. pneumoniae (n = 30) 11 (36.7) 7 (23.3)
K. oxytoca (n = 7) 2 (28.6) 0 (0)
P. mirabilis (n = 4) 2 (50) 0 (0)
P. vulgaris (n = 2) 1 (50) 0 (0)
C. freundii (n = 1) 0 (0) 0 (0)
Acinetobacter spp. (n = 1) 0 (0) 0 (0)
Total (n = 203) 70 (34.5) 50 (24.6)
The data are presented as a number (proportion, %) of uropathogens that
were MDR and ESBL producer
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This study has limitations. This study was con-
ducted in one hospital for a period of 1 year, so the
findings may not be generalisable. We could not
evaluate the risk factors and outcomes of MDR and
ESBL producers. The genotypes of ESBL producers
could not be determined.
Conclusions
We found a high prevalence of MDR and ESBL-
producing uropathogens in children in Bhaktapur,
Nepal. The prevalent uropathogens were susceptible to
nitrofurantoin, ofloxacin, and amikacin, some of which
may be used for the empirical treatment of UTIs in chil-
dren. Improved antimicrobial stewardship in hospitals
and a restricted use of over-the-counter antimicrobials
maybe some of the ways to decrease the prevalence of
antimicrobial resistance in the community.
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